Valbiotis Applauds Cardiovascular Prevention Legislation

Valbiotis, a French laboratory focusing on cardiometabolic health, has lauded the French Parliament's recent passage of legislation aimed at enhancing cardiovascular and neurovascular disease prevention. Adopted on July 20, 2026, the law emphasizes key risk factors such as high blood pressure, diabetes, and cholesterol, aiming for early detection and continuous monitoring.

This legislation aligns with Valbiotis' mission of preventing cardiometabolic imbalances before they develop into full-fledged diseases. The company's commitment is evident in initiatives like its training plans for healthcare professionals and the ValbiotisPRO® product line.

Valbiotis also supports campaigns aimed at raising awareness of cardiometabolic risks, especially in women, highlighting the societal recognition of prevention as a crucial element in healthcare. This legislative recognition comes as a strong affirmation of Valbiotis' efforts in this arena.